91983-31-2

Usage

Uses

Used in Organic Synthesis:
Methyl 5-bromo-2-hydroxy-3-nitrobenzenecarboxylate is used as a reagent for the synthesis of various organic compounds due to its versatile reactivity and synthetic utility.
Used in Pharmaceutical Research:
Methyl 5-bromo-2-hydroxy-3-nitrobenzenecarboxylate is used as a building block in the preparation of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemicals:
Methyl 5-bromo-2-hydroxy-3-nitrobenzenecarboxylate is used as a reagent in the synthesis of agrochemicals, aiding in the development of new pesticides and other agricultural chemicals.
Used in Chemical Research and Development:
Methyl 5-bromo-2-hydroxy-3-nitrobenzenecarboxylate is used as a valuable chemical in the field of chemical research and development, enabling the exploration of new chemical reactions and the creation of novel compounds.
Used in Fine Chemicals:
Methyl 5-bromo-2-hydroxy-3-nitrobenzenecarboxylate is used as a reagent in the production of fine chemicals, which are high-purity chemicals used in various industries such as pharmaceuticals, fragrances, and flavors.

Upstream product

• 22621-41-6 2-hydroxy-3-nitro-benzoic acid methyl ester 
• 22717-56-2 4-bromo-2-Hydroxybenzoic Acid Methylester 
• 4068-76-2 5-bromo-2-hydroxy-benzoic acid methyl ester 
• 69-72-7 salicylic acid 
• 119-36-8 methyl salicylate 

Downstream Products

• 141761-82-2 3-amino-5-bromo-2-hydroxybenzoic acid methyl ester 
• 35748-34-6 methyl 3-aminosalicylate 
• 141761-88-8 6-Bromo-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester 
• 141761-85-5 6-Bromo-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester 

Relevant academic research and scientific papers

WDR5-MYC INHIBITORS

Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Novel aminopyrimidine EGFR inhibitor

The present invention provides a novel aminopyrimidine compound that is a selective inhibitor of the fourth generation EGFR (T790M/C797S mutation), a pharmaceutical composition containing the compound, a useful intermediate for preparing the compound, and

DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY

Provided herein are compounds of the Formula (I), (II), and (III), as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.

Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction

The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC via the disruption of the protein-protein interaction betwee

Benzoheterocycle-carboxamide-pyridone derivatives and preparation method and applications thereof

The invention belongs to the field of chemical medicine preparation, and concretely relates to benzoheterocycle-carboxamide-pyridone derivatives, a preparation method and applications thereof. The invention provides the benzoheterocycle-carboxamide-pyridone derivatives, and a structure is represented by a formula I. The present invention also provides the preparation method and the applications ofthe above benzoheterocycle-carboxamide-pyridone derivatives. The benzoheterocycle-carboxamide-pyridone derivatives provided by the invention are novel compounds obtained on the basis of a large number of screening, inhibit EZH2 activity, and provide a novel selection for development and application of medicines for resisting tumors and autoimmune diseases.

BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists

A series of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives was synthesized and evaluated for serotonin-3 (5-HT3) receptor antagonistic activity assessed by their ability to antagonize the von Bezold-Jarish (BJ) effect in rats. Derivatives bearing 1-azabicyclo[2.2.2]oct-3-yl moiety as a basic function attached to the carboxamide at position 8 showed more potent antagonistic activity than those bearing the other three basic moieties. Structure activity relationships of this series showed that methyl and chloro groups were more effective as substituents at positions 4 and 6, respectively. The representative compound 15 (Y-25130) in this series showed potent antagonistic activity on the BJ effect (ED50 = 1.3 μg/kg i.v.), high affinity for 5-HT3 receptor (K(i) = 2.9 nM) and complete protection against cisplatin-induced emesis in dogs at a dose of 0.1 mg/kg i.v.